Last reviewed · How we verify
romosozumab HCP administration with PFS
romosozumab HCP administration with PFS is a Sclerostin inhibitor Small molecule drug developed by Amgen. It is currently in Phase 3 development for Treatment of osteoporosis in postmenopausal women at high risk of fracture. Also known as: Evenity, AMG785.
Romosozumab is a monoclonal antibody that targets sclerostin, a protein that inhibits bone formation.
Romosozumab is a monoclonal antibody that targets sclerostin, a protein that inhibits bone formation. Used for Treatment of osteoporosis in postmenopausal women at high risk of fracture.
At a glance
| Generic name | romosozumab HCP administration with PFS |
|---|---|
| Also known as | Evenity, AMG785 |
| Sponsor | Amgen |
| Drug class | Sclerostin inhibitor |
| Target | Sclerostin |
| Modality | Small molecule |
| Therapeutic area | Osteoporosis |
| Phase | Phase 3 |
Mechanism of action
By binding to sclerostin, romosozumab increases bone formation and decreases bone resorption, leading to increased bone density and reduced risk of fractures. This mechanism is thought to be beneficial in the treatment of osteoporosis and other bone-related disorders.
Approved indications
- Treatment of osteoporosis in postmenopausal women at high risk of fracture
Common side effects
- Back pain
- Headache
- Musculoskeletal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- romosozumab HCP administration with PFS CI brief — competitive landscape report
- romosozumab HCP administration with PFS updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about romosozumab HCP administration with PFS
What is romosozumab HCP administration with PFS?
How does romosozumab HCP administration with PFS work?
What is romosozumab HCP administration with PFS used for?
Who makes romosozumab HCP administration with PFS?
Is romosozumab HCP administration with PFS also known as anything else?
What drug class is romosozumab HCP administration with PFS in?
What development phase is romosozumab HCP administration with PFS in?
What are the side effects of romosozumab HCP administration with PFS?
What does romosozumab HCP administration with PFS target?
Related
- Drug class: All Sclerostin inhibitor drugs
- Target: All drugs targeting Sclerostin
- Manufacturer: Amgen — full pipeline
- Therapeutic area: All drugs in Osteoporosis
- Indication: Drugs for Treatment of osteoporosis in postmenopausal women at high risk of fracture
- Also known as: Evenity, AMG785
- Compare: romosozumab HCP administration with PFS vs similar drugs
- Pricing: romosozumab HCP administration with PFS cost, discount & access